Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...

Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in ...

Stryker is selling off its spine implant business—starting with a plan to spin off its U.S. operations before moving on to ...

Pregnancy comes with unique health risks and considerations, but pregnant people also continue to experience the same health ...

Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced ...

Zimmer Biomet is taking steps to expand its foot and ankle orthopedics business, with a $1.1 billion deal to acquire the ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

The FDA’s move to lift the hold on Zentalis Pharmaceuticals’ sole clinical-stage drug may have been good news for the biotech ...

Demand slipped for several large contract research organizations last year, and a new report from William Blair analysts ...

A judge has ruled against investor Alcon Research on the matter of blocking investee Aurion Biotech from debuting on the ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...